MedTrace Logo

Phase II Study of Range and Schedule of rPA Doses

NCT00170456 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 415

Last updated 2008-09-15

No results posted yet for this study

Summary

This is a dose ranging study comparing different vaccine schedules of rPA vaccine for anthrax. Safety and the capability to induce an immune response will be evaluated.

Conditions

  • Prevention of Bacillus Anthracis (Anthrax) Infection

Interventions

BIOLOGICAL

rPA vaccine containing alhydrogel

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • PharmAthene UK Limited

    lead INDUSTRY

Principal Investigators

  • Timothy Mant, MD · GDRU, London, UK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-01-31
Completion
2007-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170456 on ClinicalTrials.gov